» Articles » PMID: 35332111

Recent Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease

Overview
Date 2022 Mar 25
PMID 35332111
Authors
Affiliations
Soon will be listed here.
Abstract

Because of the global obesity epidemic, the incidence and prevalence of nonalcoholic fatty liver disease (NAFLD) have increased worldwide, including among Koreans. Recently, the incidence rate of NAFLD in Korea was reported to be 45.1 per 1,000 person-years, and the prevalence as approximately 30% depending on the diagnostic methods used. The incidence of advanced fibrosis and hepatocellular carcinoma, as well as all-cause and liver-related mortality in NAFLD patients has increased substantially, imposing considerable public health costs in Korea. Genetic, demographic, environmental, and clinical factors are involved in the pathogenesis of NAFLD. Some genetic variants, such as patatin-like phospholipase domain-containing 3 () and sorting and assembly machinery component 50 (), play a major role in the occurrence of NAFLD. The risk of NAFLD and fibrosis increases with advancing age and in men. Nutritional factors, inadequate exercise, and sleep duration are also associated with increased risk of NAFLD. Obesity is a major risk factor for NAFLD; however, NAFLD in lean individuals has been noted in recent studies. Insulin resistance, type 2 diabetes, and metabolic syndrome and its components are closely associated with NAFLD development and liver fibrosis with various underlying mechanisms. Sarcopenia likely shares a common pathophysiology with NAFLD. The rapidly increasing incidence and prevalence of NAFLD and its complications, as well as the associated healthcare burden, warrant early assessment of NAFLD and its risk factors to prevent NAFLD-related complications in high risk groups.

Citing Articles

Untargeted lipidomic analysis of metabolic dysfunction-associated steatohepatitis in women with morbid obesity.

Bertran L, Capellades J, Abello S, Richart C PLoS One. 2025; 20(3):e0318557.

PMID: 40036208 PMC: 11878907. DOI: 10.1371/journal.pone.0318557.


Establishing of a risk prediction model for metabolic dysfunction-associated steatotic liver disease: a retrospective cohort study.

Li N, Liu C, Lu Z, Wu W, Zhang F, Qiu L BMC Gastroenterol. 2025; 25(1):39.

PMID: 39875811 PMC: 11773756. DOI: 10.1186/s12876-025-03598-4.


Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease.

Orfanidou M, Polyzos S Medicina (Kaunas). 2025; 61(1).

PMID: 39859020 PMC: 11766779. DOI: 10.3390/medicina61010038.


Extracellular vesicle-mediated approaches for the diagnosis and therapy of MASLD: current advances and future prospective.

Gurjar S, Bhat A R, Upadhya R, Shenoy R Lipids Health Dis. 2025; 24(1):5.

PMID: 39773634 PMC: 11705780. DOI: 10.1186/s12944-024-02396-3.


subsp. CKDB001 Ameliorates Metabolic Complications in High-Fat Diet-Induced Obese Mice.

Jang H, Joung H, Chu J, Cho M, Kim Y, Kim K Nutrients. 2025; 16(24.

PMID: 39770882 PMC: 11677567. DOI: 10.3390/nu16244260.


References
1.
Lu W, Li S, Li J, Wang J, Zhang R, Zhou Y . Effects of Omega-3 Fatty Acid in Nonalcoholic Fatty Liver Disease: A Meta-Analysis. Gastroenterol Res Pract. 2016; 2016:1459790. PMC: 5019889. DOI: 10.1155/2016/1459790. View

2.
van der Heijden G, Wang Z, Chu Z, Sauer P, Haymond M, Rodriguez L . A 12-week aerobic exercise program reduces hepatic fat accumulation and insulin resistance in obese, Hispanic adolescents. Obesity (Silver Spring). 2009; 18(2):384-90. DOI: 10.1038/oby.2009.274. View

3.
Allen A, Therneau T, Larson J, Coward A, Somers V, Kamath P . Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study. Hepatology. 2017; 67(5):1726-1736. PMC: 5866219. DOI: 10.1002/hep.29546. View

4.
Aithal G, Thomas J, Kaye P, Lawson A, Ryder S, Spendlove I . Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008; 135(4):1176-84. DOI: 10.1053/j.gastro.2008.06.047. View

5.
Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo-Perez F . The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2015; 63(3):764-75. PMC: 4975935. DOI: 10.1002/hep.28356. View